<DOC>
	<DOCNO>NCT02557308</DOCNO>
	<brief_summary>An Observational , Prospective Cohort Study Evaluate Safety Efficacy RemsimaTM Patients Ankylosing Spondylitis</brief_summary>
	<brief_title>An Observational Study Evaluate Safety Efficacy Remsima™ Patients With Ankylosing Spondylitis</brief_title>
	<detailed_description>The primary objective study assess safety Remsima™ ankylose spondylitis ( AS ) patient , comparison patient receive anti-TNF drug , evaluation event special interest ( ESI ) 5 year first visit patient . In order ass primary study outcome , follow ESI evaluate : Identified risk : - Hepatitis B virus reactivation - Congestive heart failure - Opportunistic infection ( exclude tuberculosis ) - Serious infection include sepsis ( exclude opportunistic infection tuberculosis ) - Tuberculosis - Serum sickness ( delay hypersensitivity reaction ) - Haematologic reaction - Systemic lupus erythematosus/lupus-like syndrome - Demyelinating disorder - Lymphoma ( HSTCL ) - Hepatobiliary event - Hepatosplenic T-cell Lymphoma ( HSTCL ) - Serious infusion reaction re-induction follow disease flare - Sarcoidosis/sarcoid-like reaction - Leukaemia Potential risk : - Malignancy ( exclude lymphoma ) - Skin cancer - Pregnancy exposure† The secondary objective study evaluate efficacy additional safety Remsima™ AS patient , comparison patient receive TNF blocker .</detailed_description>
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylitis , Ankylosing</mesh_term>
	<criteria>1 . Adult patient 2 . Patients active AS 3 . Patients ( legal guardian , applicable ) willing give inform consent long term followup include access medical record 1 . Patients history hypersensitivity infliximab 2 . Patients current past history chronic infection 3 . Patients moderate severe heart failure ( NYHA class III/IV ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>